Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.70 |
| ▸ | AKT2 | P31751 | 4/20 | 0.70 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.70 |
| ▸ | PLCG2 | P16885 | 2/20 | 0.65 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082266 | 1.00 | AKT1 (0.70) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL4565034 | 0.95 | AKT1 (0.64) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL17416063 | 0.90 | AKT1 (0.85) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL5446081 | 0.90 | AKT1 (0.85) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL4199434 | 0.90 | AKT1 (0.85) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL30898875 | 0.85 | GPR55 (0.69) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL4601441 | 0.83 | AKT1 (0.57) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL11131399 | 0.82 | LPAR1 (0.56) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL13058680 | 0.82 | AKT1 (0.58) | AKT1AKT2AKT3PIK3R1PIK3CA | |
| SCHEMBL11004956 | 0.80 | PLCG2 (0.66) | AKT1AKT2AKT3PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-2429658-B1 | Method for adjuvating the lipopolysaccharide (LPS) of gram-negative bacteria | SANOFI PASTEUR (FR) | 2016-04-20 | — | — | EP | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| EP-2430151-B1 | MENINGOCOCCAL VACCINE CONSTITUTED OF LIPOOLIGOSACCHARIDES FROM MODIFIED IMMUNOTYPE L6 NEISSERIA MENINIGITIDIS | SANOFI PASTEUR (FR) | 2014-06-18 | — | — | EP | disclosed |
| EP-2429576-A1 | MENINGOCOCCAL VACCINE BASED ON LIPOOLIGOSACCHARIDE (LOS) AND NEISSERIA MENINGITIDIS PROTEIN | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429658-A2 | METHOD FOR ADMIXING THE LIPOPOLYSACCHARIDE (LPS) OF GRAM-NEGATIVE BACTERIA | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430151-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | Sanofi Pasteur (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010130899-A1 | MENINGOCOCCAL VACCINE BASED ON LIPOOLIGOSACCHARIDE (LOS) AND NEISSERIA MENINGITIDIS PROTEIN | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130898-A2 | MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130896-A2 | METHOD FOR ADMIXING THE LIPOPOLYSACCHARIDE (LPS) OF GRAM-NEGATIVE BACTERIA | SANOFI PASTEUR (FR) | 2010-11-18 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-6042622-A | Process for crystallization of alkali metal bicarbonate salts | BASF CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| US-5716419-A | Process for crystallization of mineral salts | PPG INDUSTRIES, INC. (US) | 1998-02-10 | — | — | US | disclosed |